Innovent Biologics, Inc. (FRA:6IB)
Germany · Delayed Price · Currency is EUR | Market Cap | 16.49B +1.9% |
| Revenue (ttm) | 2.02B +37.5% |
| Net Income | 158.80M +8.8% |
| EPS | 0.09 +3.1% |
| Shares Out | n/a |
| PE Ratio | 102.47 |
| Forward PE | 40.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 9.37 |
| Previous Close | 9.15 |
| Day's Range | 9.37 - 9.37 |
| 52-Week Range | 7.91 - 12.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 25, 2026 |
About Innovent Biologics
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimum... [Read more]
News
Innovent Reports Phase 3 Success For Arcotatug Tavatecan In Gastric Cancer
(RTTNews) - Innovent Biologics (1801.HK) announced positive results from its Phase 3 G-HOPE-001 study of arcotatug tavatecan (IBI343), an investigational CLDN18.2-targeted antibody-drug conjugate (ADC...
Innovent's Arcotatug Tavatecan Meets Phase 3 Endpoints In Gastric Cancer
(RTTNews) - Innovent Biologics (IVBXF) announced that its Phase 3 G-HOPE-001 study of arcotatug tavatecan met both primary endpoints of overall survival (OS) and progression-free survival (PFS) in pre...
Innovent's Phase 3 Success Expands SYCUME's Potential In Thyroid Eye Disease
(RTTNews) - Innovent Biologics announced that its Phase 3 RESTORE-3 study of SYCUME (teprotumumab N01 injection) met the primary endpoint in Chinese patients with inactive thyroid eye disease (TED), m...
Innovent's SYCUME Delivers Phase 3 Win In Inactive Thyroid Eye Disease
(RTTNews) - Innovent's SYCUME Delivers Phase 3 Win in Inactive Thyroid Eye Disease
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) SAN FRANCISC...
Innovent Reports Updated Phase 1 Data For IBI3003 In Relapsed/Refractory Multiple Myeloma
(RTTNews) - Innovent Biologics, Inc. (1801.HK), a biopharmaceutical company, announced updated Phase 1 clinical data for IBI3003 in patients with relapsed or refractory multiple myeloma (R/R MM), pres...
Innovent's Jaypirca Gets Expanded NMPA Approval For CLL/SLL
(RTTNews) - Innovent Biologics, Inc. (IVBXF) announced that China's National Medical Products Administration (NMPA) has approved Jaypirca (pirtobrutinib) as a monotherapy for adults with chronic lymph...
Innovent Biologics announces China NMPA approves Jaypirca for new indication
Innovent Biologics (IVBXF) announced that the China National Medical Products Administration has approved Jaypirca, a non-covalent Bruton tyrosine kinase inhibitor, as a monotherapy for the treatment ...
Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy
SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercial...
Innovent Expands Phase 3 IBI363 Study To Non-Squamous Lung Cancer; Stock Down
(RTTNews) - Innovent Biologics, Inc. (1801.HK), a biopharmaceutical company focused on developing therapies across oncology and other major diseases, announced the expansion of the global Phase 3 Mars...
Innovent Biologics announces expansion of global Phase 3 MarsLight-11 trial
Innovent Biologics (IVBXF) announces expansion of the global Phase 3 MarsLight-11 trial, which is evaluating IBI363 in patients with squamous non-small cell lung cancer, NSCLC, whose disease has progr...
Altruist Biologics' Suzhou Facility Clears EMA GMP Inspection
(RTTNews) - Altruist Biologics, a contract development and manufacturing organization (CDMO) and wholly owned subsidiary of Innovent Biologics (1801.HK,IVBXF), announced that its commercial manufactur...
Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting
SAN FRANCISCO and SUZHOU, China, Sept. 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali...
Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
Chinese biopharma stocks advanced Monday, with Innovent Biologics jumping 7% and Akeso up 8% after a report that the U.S. may allow most drug licensing deals with Chinese firms to continue. The propo...
Innovent Biologics Earnings release: H1 2026
Innovent Biologics released its H1 2026 earnings on August 25, 2026, summarizing the period's financial results.
Innovent Biologics Slides: H1 2026
Innovent Biologics has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 25, 2026.
Innovent Biologics Quarterly report: H1 2026
Innovent Biologics has published its H1 2026 quarterly earnings report on August 25, 2026.
Daiichi Sankyo, Innovent enter exclusive agreement for Vanflyta in China
Innovent Biologics (IVBXF) and Daiichi Sankyo (DSNKY) have entered into an exclusive agreement for the commercialization of Vanflyta in China. Under the terms of the agreement, Daiichi Sankyo will be…
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML SAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK...
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
Spero Therapeutics has licensed rights outside Greater China to develop and commercialize Innovent Biologics' experimental autoimmune disease treatment in a deal worth up to about $1.1 billion, the ...
Spero Therapeutics, Innovent Biologics enter license agreement for SP001
Spero Therapeutics (SPRO) and Innovent Biologics (IVBXF) announced an exclusive license agreement for SP001, a third-generation Fc-silent anti-CD40L antibody. Spero will receive exclusive rights to de...
Innovent Biologics, Eli Lilly enters Verzen distribution and promotion agreement
Innovent Biologics (IVBXF) and Eli Lilly (LLY) jointly announced that they have entered into a distribution and promotion agreement regarding Lilly’s CDK4 & 6 inhibitor Verzenios in mainland China. In...
China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug
Innovent Biologics has entered into an agreement that grants it sole commercialization rights for Eli Lilly's breast cancer drug Verzenios in mainland China, the Chinese drugmaker said Tues...
Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review
Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide injection have passed a preliminary review to be potentially included in China's basic medical insurance drug catalogue, a ...
Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026
SAN FRANCISCO and SUZHOU, China, June 24, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commerciali...